XML 72 R63.htm IDEA: XBRL DOCUMENT v3.23.2
Equity Offerings (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Apr. 05, 2023
Apr. 03, 2023
Jul. 15, 2022
Jun. 01, 2022
Apr. 19, 2022
Apr. 13, 2022
Apr. 05, 2022
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Proceeds from issuance of common stock                   $ 13,848,000 $ 32,812,000
Conversion of stock description           The holder will be prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation solely as to itself up to 19.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)       A holder is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)  
Percentage of issued and outstanding shares           4.99%          
Conversion price percentage     140.00%                
Net proceeds to immediately redeem                  
Purchase of warrant               819,767   819,767  
Maximum [Member]                      
Warrant exercise price per share               $ 109.20   $ 109.20  
Over-Allotment Option [Member]                      
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares           196,998          
Proceeds from issuance initial public offering         $ 32,800,000            
April 2022 Warrants [Member] | Over-Allotment Option [Member]                      
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares           1,313,320          
April 2022 Warrants [Member] | IPO [Member]                      
Purchase of warrant           1,313,320          
Sale of stock, price per share           $ 26.65          
Common Stock [Member]                      
Net proceeds to immediately redeem                  
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares                 1,313,000   1,314,000
Shares issued price per share           $ 0.20          
Common Stock [Member] | IPO [Member]                      
Purchase of warrant           656,660          
Shares issued price per share           $ 26.45          
Warrant [Member] | IPO [Member]                      
Warrant exercise price per share           $ 0.20          
Registered Direct Offering [Member]                      
Proceeds from issuance of common stock   $ 13,900,000                  
Registered Direct Offering [Member] | Board Members [Member]                      
Shares issued price per share   $ 7.08                  
Registered Direct Offering [Member] | Other Investors [Member]                      
Shares issued price per share   $ 6.03                  
Registered Direct Offering [Member] | Maximum [Member]                      
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares   2,278,121                  
Registered Direct Offering [Member] | Maximum [Member] | Board Members [Member]                      
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares   2,278,121                  
Underwriting Agreement [Member]                      
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares           196,998          
Shares issued price per share           $ 24.85          
Underwriting Agreement [Member] | April 2022 Warrants [Member]                      
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares           196,998          
Underwriting Agreement [Member] | Common Stock [Member]                      
Purchase of warrant           98,499          
Underwriting Agreement [Member] | Warrant [Member]                      
Purchase of warrant           196,998          
Series A Preferred Stock [Member]                      
Stock issued during period, shares, conversion of units           11,765 588.23529        
Preferred stock, convertible, shares issuable           384,477          
Preferred stock, convertible, conversion price           $ 30.60          
Purchase price           850          
Stated value           $ 1,000          
Proceeds from issuance of preferred stock and preference stock           $ 10,000,000          
Preferred stock outstanding percentage           51.00%          
Cash in hand           $ 8,000,000          
Indebtedness expenses           $ 15,000,000          
Preferred stock, dividend rate, percentage                   6.00%  
Dividends, preferred stock                   $ 321,000  
Number of shares issued               4,818   4,818  
Number of shares outstanding               4,818   4,818  
Series A Preferred Stock [Member] | Oncocyte Corp [Member]                      
Equity method investment description     if the daily volume weighted average price of our common stock for 20 out of 30 trading days exceeds 140% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000 shares of our common stock             if the daily volume weighted average price of our common stock for 20 out of 30 trading days exceeds 140% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000 shares of our common stock  
Series A Preferred Stock [Member] | Oncocyte Corp [Member] | Preferred Stock [Member]                      
Ownership percentage           50.00%          
Series A Preferred Stock [Member] | Security [Member] | Preferred Stock [Member]                      
Ownership percentage           50.00%          
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member] | Share-Based Payment Arrangement, Tranche One [Member]                      
Proceeds from issuance of common stock       $ 4,900,000              
Series A Preferred Stock [Member] | Registered Direct Offering [Member]                      
Net proceeds to immediately redeem $ 1,100,000 $ 1,100,000                  
Number of stock redeem 1,064                    
Series A Preferred Stock [Member] | Two Equal Tranches [Member]                      
Proceeds from issuance of preferred stock and preference stock           $ 5,000,000          
Series B Preferred Stock [Member] | Registered Direct Offering [Member]                      
Net proceeds to immediately redeem   $ 1,100,000                  
Number of stock redeem   1,064